Clinical trial
IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH)
NCT03775109 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH)
- Lead sponsor
- Imperial College London
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 12, 2019
- Completion date
- March 31, 2023
- Enrollment
- 55 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
alcoholic hepatitis